Skip to main content

Table 4 Clinical treatment and short-term outcomes in AECOPD patients

From: Aspergillus fumigatus during COPD exacerbation: a pair-matched retrospective study

 

Aspergillus colonization, n = 23

Control, n = 69

p value

Admitted in ICU

4 (17.4%)

11 (15.9%)

1.000

Machined ventilation

3 (13.0%)

9 (13.0%)

0.906

Antibiotics

21 (95.5%)

66 (95.7%)

1.000

 More than 1 class

52.2%

21.7%

0.006

 Duration of treatment (days)

13 ± 5

10 ± 4

0.003

Corticosteroid use

17 (77.3%)

42 (60.9%)

0.204

 Systemic only

0

2 (2.90%)

1.000

 Inhalation only

8 (34.8%)

20 (29.0%)

0.601

Dose of usage

 Budesonide (inhaled,≥40 mg)

30.4%

5.8%

0.002

 Methylprednisolone (iv,≥120 mg)

39.1%

31.9%

0.524

Bronchodilators (aerosol inhalation)

21 (91.3%)

57 (82.6%)

0.505

 Ipratropium Bromide (mg)

16.3 ± 11.6

14.8 ± 8.2

0.631

 Salbutamol (mg)

115 ± 98

83 ± 53

0.308

Remission time (days)

11 ± 4

7 ± 4

0.001

Duration of hospitalization (days)

15 ± 5

12 ± 4

0.011

  1. Italicized p-values are statistically significant, ie. p < 0.05